Table 4.
Correlation analysis between changes of ADS markers and reduction of clinical symptoms.
| - | P scoreb | N scoreb | G scoreb | Total scoreb |
|---|---|---|---|---|
| Males (r, p) | ||||
| GPx (U/ml)a | -0.8 (.41) | -.03 (.79) | .16 (.08) | .11 (.25) |
| CAT (U/ml)a | .05 (.58) | -.09 (.38) | .08 (.39) | .04 (.72) |
| SOD (U/ml)a | .13 (.17) | -.07 (.45) | .17 (.07) | .10 (.25) |
| TAS (U/ml)a | .19 (.03)* | .01 (.95) | .10 (.25) | .13 (.15) |
| Females (r, p) | ||||
| GPx (U/ml)a | -.32 (.001)** | .04 (.69) | -.23 (.02)* | -.22 (.03)* |
| CAT (U/ml)a | .04 (.74) | -.06 (.59) | .04 (.71) | .02 (.85) |
| SOD (U/ml)a | .01 (.92) | -.06 (.59) | -.07 (.51) | -.05 (.62) |
| TAS (U/ml)a | .03 (.75) | -.10 (.35) | -.04 (.69) | -.02 (.82) |
Note: a means the changes in the levels of ADS markers after treatment with risperidone for 12 weeks; b means the reductions in the clinical symptoms after treatment with risperidone for 12 weeks; * p < 0.05, **p < 0.01.